NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders, including suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia, in the United States. It operates through the NRx and Dura segments. Its pipeline includes NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. The company also provides precision-based interventional psychiatry services for patients with treatment-resistant depression and PTSD, using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy, as well as ketamine infusion therapy, stellate ganglion blocks, Spravato administration, psychotherapy, and medication management. It has a development and license agreement with Glytech LLC, was founded in 2015, and is headquartered in Wilmington, Delaware.